According to a recent LinkedIn post from Neuromod Devices Ltd, audiologist Dr. Laura Bradley Pratesi is scheduled to lead a session at the American Academy of Audiology 2026 focused on future approaches to tinnitus care. The session, titled “Tinnitus Treatments of 2026: Bimodal Stimulation and Biometric Tracking,” is set for Friday, April 24 at 11:15 a.m.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that the session will discuss synchronized bimodal neuromodulation, including what is described as the first FDA‑approved bimodal neuromodulation device, Lenire. It also notes that emerging biometric tracking tools are expected to influence how clinicians manage patients with bothersome tinnitus.
For investors, the content suggests Neuromod Devices is emphasizing clinical education and positioning its Lenire device within forward‑looking standards of care for tinnitus. Increased professional awareness and conference visibility may support broader clinical adoption, which could translate into higher device utilization and recurring revenue potential over time.
The focus on biometric tracking and advanced neuromodulation also points to a strategy that aligns with digital health and data‑driven care trends in audiology. If these technologies gain traction among ENT specialists and audiologists, Neuromod Devices could strengthen its competitive position in a niche but growing segment of tinnitus treatment.